|  |
Technical Reports |
| You may download our technical reports or you can order them here. |
|
| |
|
|
|
|
|
 | Front-End Engineering - A New Design Approach for Biotechnology Projects
>>> Download (PDF, 785,6Kb)
>>> Do you have Acrobat Reader? |
 | |
 | Future market: biotechnology - Demands on the conception of biotechnological plantsIn search of new drugs the pharmaceutical industry today is profiting greatly from the dynamic growth in knowledge of genetics and cell biology. Innovative drugs are produced for example by genetically modified cells and permit completely new therapeutic approaches. Culture of such cells and recovery of their products on an indurstrial scale place complex demands on the conception of biotechnological plant.
>>> Download (PDF, 300,5Kb)
>>> Do you have Acrobat Reader? |
| |
 | New Trends in Pharmaceutical Industry - Future Market: BiotechnologyThe biotechnological production of novel drug substances, for instance for anti-cancer treatment, places special demands on plant design and construction: In a period of dynamic developments in biotechnology, trends must be recognized in timely fashion and answered with flexible structures for design and execution. Due to the implementation of front-end engineering, Linde-KCA Dresden is a market leader in biotechnological plant design and construction and is well positioned to master the challenges of the future market of biotechnology.
>>> Download (PDF, 647,8Kb)
>>> Do you have Acrobat Reader? |
| |
 | Practical Execution of a Retrospective QualificationThe GMP (Good Manufacturing Practice) concept was developed to have a high probability of being able to prevent hazards to human life from taking medicines that are not of good quality. The GMP concept says that the necessary product quality can be achieved only by measures that go beyond controls on the quality of the immediate processes for producing the pharmaceuticals.
>>> Download (PDF, 422,7Kb)
>>> Do you have Acrobat Reader? |
| |
 | Front-End Engineering for Pharmaceutical Plants - New Design Approach for Biotechnology ProjectsLinde-KCA's Front-End Engineering Approach bridges the gap between research & development and biopharmaceutical production. It was developed specifically to enable reliable evaluation of status, risks, costs and schedule during the early phase of biotechnological high tech projects with the goal of fast-track realization. That can minimize risks and optimize the schedule for planning and construction of plants. The result is reliability of plans and decisions for both the client and for the plant designer. The need for front-end engineering services has been identified both on the route from the laboratory to biopharmaceutical production in biotech companies, as well as in established pharmaceutical companies.
>>> Download (PDF, 269,5Kb)
>>> Do you have Acrobat Reader? |
| |
 | Biotechnology Plant for Insulin ProductionRecombinant human insulin produced by genetically modified bacteria is one of the Top products of "red" biotechnology. Linde-KCA has built one of the technologically most advanced production plants in the world for this kind of product. The new and very specific demands on the engineering and construction company made by such a large scale Biotech project have recently been reported by the Linde-KCA project manager.
>>> Download (PDF, 278,8Kb)
>>> Do you have Acrobat Reader? |
| |
 | Modernizing while production continuesCompanies in the pharmaceutical industry are continually challenged to modernize and expand their existing production facilities in order to meet the quality requirements for pharmaceutical agents and the equipment used to manufacture those products. Nevertheless, at the same time, plant operators are not willing to tolerate production downtimes while improvements are being made. For engineering companies such as Linde-KCA-Dresden, this means having the foresight to plan the entire project in great detail. A good example is the customer BIOTEST Pharma GmbH near Frankfurt, Germany.
>>> Download (PDF, 275,5Kb)
>>> Do you have Acrobat Reader? |
|
| |
|
|
|
| |
|
